BCOP Updates 2023: Updates in the treatment of Relapsed/Refractory DLBCL
Treatment for diffuse large B-cell lymphoma (DLBCL) is generally well-defined in the first-line setting, with R-CHOP being the standard of care for all but the more aggressive variants of this disease. In the relapsed/refractory (r/r) setting, however, second-line treatment historically branches between those eligible to proceed to high dose chemotherapy with autologous stem cell rescue and those not deemed not candidates for transplant. In recent years, the landscape of r/r DLBCL treatment has begun to change significantly, with chimeric antigen receptor T-cell (CAR-T) therapy, bispecific T-cell engagers (BiTE) and other targeted agents providing novel options with similar or improved tolerability. However, these options are costly and have operational barriers that make usage difficult to implement. With multiple new treatment options challenging historical standards of care, it is essential for the oncology pharmacist to possess a working knowledge of new agents and the evidence at the foundation of their FDA approvals. This session will review the most updated guidelines; landmark literature on recently-approved agents; and evaluate their potential places in therapy.